Lomitapide (Juxtapid) Coverage for Homozygous Familial Hypercholesterolemia
Customize your policy alerts
Sign up for blue cross blue shield - louisiana Policy 00243 alerts
Get alerted when Policy 00243 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization coverage of lomitapide (Juxtapid) for eligible members with homozygous familial hypercholesterolemia, including initial therapy and reauthorization. Coverage requires available benefits, medical necessity, and satisfaction of the stated patient-selection criteria.
Lomitapide coverage was revised to include patients 2 years of age and older with homozygous familial hypercholesterolemia.
Patient-selection criteria were revised to require adherence to prerequisite lipid-lowering therapy and risk-based LDL-C thresholds.
HoFH diagnostic criteria were clarified.
Statin-intolerance definitions and prerequisite-therapy exceptions were updated.
Reauthorization criteria for continued lomitapide therapy were added.
The policy clarified that Juxtapid should not be used with Kynamro, PCSK9 inhibitors, or ATP citrate lyase inhibitors.
Coverage Criteria
Initial Therapy Criteria
Initial coverage is considered when ALL of the following criteria are met.
Initial therapy
Basic eligibility
- The patient is at least 2 years of age and is adherent to medications required before authorization for lomitapide.Age ≥2 years
Required background therapy
- Lomitapide will be used with a maximally tolerated statin in patients who are not statin intolerant, a maximally dosed PCSK9 inhibitor, and generic ezetimibe 10 mg daily.
The PCSK9 inhibitor requirement does not apply when the patient has two LDL-receptor-negative alleles.
Clinical HoFH diagnosis
Genetic confirmation
- Two mutant alleles are genetically confirmed at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus.Two mutant alleles
Untreated LDL-C pathway
- Untreated LDL-C is greater than 400 mg/dL and the patient has either clinical manifestations of HoFH before age 10 or both parents with untreated LDL-C or total cholesterol levels consistent with HeFH.Untreated LDL-C >400 mg/dL
Clinical manifestations include cutaneous or tendon xanthomas, arcus cornea, tuberous xanthomas, or xanthelasma.
Supporting finding
- Clinical manifestations of HoFH occurred before age 10, or both parents had untreated lipid levels consistent with HeFH.Parent example: LDL-C ≥190 mg/dL and/or total cholesterol >250 mg/dL
Treated LDL-C pathway
- Treated LDL-C is at least 300 mg/dL and the patient has either clinical manifestations of HoFH before age 10 or both parents with untreated LDL-C or total cholesterol levels consistent with HeFH.Treated LDL-C ≥300 mg/dL
Treated LDL-C is measured after therapy with at least one antihyperlipidemic agent.
Supporting finding
- Clinical manifestations of HoFH occurred before age 10, or both parents had untreated lipid levels consistent with HeFH.Parent example: LDL-C ≥190 mg/dL and/or total cholesterol >250 mg/dL
Prerequisite therapy and LDL-C response
Standard statin and ezetimibe pathway
- The patient has tried a high-intensity statin at the maximum daily dose for at least 12 continuous weeks, or a maximally tolerated stable daily statin dose for at least 12 continuous weeks when maximum-dose high-intensity therapy was not well tolerated; has taken generic ezetimibe 10 mg daily with the statin for at least 12 continuous weeks; and has residual LDL-C at or above the applicable risk-based threshold.Atorvastatin ≥80 mg/day or rosuvastatin ≥40 mg/day; therapy ≥12 continuous weeks; LDL-C ≥70 mg/dL for high risk or ≥55 mg/dL for very high risk
Statin-intolerance pathway
- The patient has residual LDL-C at or above the applicable risk-based threshold due to statin intolerance, has taken generic ezetimibe 10 mg daily without a statin for at least 12 continuous weeks, and meets the statin-intolerance requirements.LDL-C ≥70 mg/dL for high risk or ≥55 mg/dL for very high risk
Statin intolerance requirements
- The patient was unable to tolerate at least two different statins, or one statin if rhabdomyolysis or clinically significant myonecrosis occurred; the adverse effects were confirmed and intolerable statin-related myopathy or myalgia; and symptoms or biomarker changes resolved or significantly improved after dose reduction or discontinuation.CK ≥10 times the upper limit of normal
The one-statin exception applies to qualifying rhabdomyolysis or clinically significant myonecrosis.
PCSK9 inhibitor requirement or exception
PCSK9 inhibitor trial
- The patient has tried a PCSK9 inhibitor for at least 12 continuous weeks at the FDA-approved maximum dose for HoFH and residual LDL-C remains at or above the applicable threshold.Evolocumab 420 mg every 2 weeks or alirocumab 150 mg every 2 weeks; therapy ≥12 continuous weeks; LDL-C ≥70 mg/dL for high risk or ≥55 mg/dL for very high risk
LDL-receptor genotype exception
- The patient is known to have two LDL-receptor-negative alleles.Two negative alleles
Young pediatric exception
- The patient is 2 to 9 years of age.Age 2–9 years
Re-authorization Criteria
Re-authorization requires ALL of the following.
Continuation therapy
- The patient previously met the initial criteria and received approval for lomitapide.
Prior approval must be documented.
- The patient has achieved clinically significant LDL-C lowering and remains adherent to lomitapide.Clinically significant LDL-C lowering
Investigational or experimental use is excluded from coverage, including any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study.
Juxtapid should not be used with Kynamro or PCSK9 inhibitors.
Juxtapid should not be used in combination with ATP citrate lyase (ACL) inhibitors.
Use is considered not medically necessary when required prerequisite medications have not been tried for at least 12 continuous weeks, when re-authorization criteria are not met, or when the patient is not adherent to the cholesterol-lowering regimen.
Clinical Thresholds and Operational Values
Authorization and Documentation Requirements
Initial Authorization Required
Prior authorization is required. Coverage may be considered only when benefits are available under the member’s contract and all medical-necessity and patient-selection requirements are met for lomitapide (Juxtapid) use in homozygous familial hypercholesterolemia (HoFH).
- Patient is at least 2 years of age.
- Patient is adherent to medications required before authorization.
- Patient meets the required HoFH diagnostic pathway.
- Required prerequisite lipid-lowering therapy, treatment durations, doses, and LDL-C response are documented.
- Initial approval requires the applicable statin, ezetimibe, and PCSK9-inhibitor criteria, including statin-intolerance documentation when applicable.
Re-authorization Requirements
Re-authorization requires documentation that the patient previously met the initial criteria and received approval for lomitapide, has achieved clinically significant LDL-C lowering, and remains adherent to lomitapide.
- Re-authorization criteria are additional Company requirements.
- Failure to meet continuation requirements may result in denial as not medically necessary.
Required Lipid-Lowering Sequence
Before lomitapide is authorized, document the required lipid-lowering sequence unless an exception applies. Use lomitapide with a maximally tolerated statin, maximally dosed PCSK9 inhibitor, and generic ezetimibe 10 mg daily when required.
- The statin requirement does not apply when the patient is documented as statin intolerant.
- The PCSK9-inhibitor requirement does not apply when the patient has two LDL-receptor-negative alleles or is 2–9 years of age under the applicable criterion.
- Document the applicable exception and supporting clinical evidence.
HoFH Diagnostic Evidence
Submit clinical documentation establishing HoFH through at least one accepted pathway. The patient must meet the applicable genetic, untreated LDL-C, treated LDL-C, clinical-manifestation, or family-history requirements.
- Genetic pathway: two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 locus.
- Untreated pathway: LDL-C greater than 400 mg/dL plus clinical HoFH manifestations before age 10 or both parents with untreated values consistent with HeFH.
- Treated pathway: LDL-C at least 300 mg/dL plus clinical HoFH manifestations before age 10 or both parents with untreated values consistent with HeFH.
- Document relevant xanthomas, arcus cornea, xanthelasma, genetic results, untreated or treated LDL-C values, and parental lipid history.
Prerequisite Medication History
Document the patient’s complete prerequisite medication history before requesting lomitapide, including adherence, medication names, doses, treatment dates, and LDL-C results.
- Record use of high-intensity or maximally tolerated statin therapy, generic ezetimibe 10 mg daily, and PCSK9-inhibitor therapy when applicable.
- Document the FDA-approved maximum PCSK9-inhibitor dose used for HoFH.
- If the patient is statin intolerant, document ezetimibe use without a statin and the qualifying intolerance evidence.
Therapy Duration and LDL-C Results
Coverage requires evidence that prerequisite therapy was used for at least 12 continuous weeks and that LDL-C remains above the applicable threshold after treatment.
- High-intensity statin examples: atorvastatin at least 80 mg daily or rosuvastatin at least 40 mg daily, unless a maximally tolerated stable statin dose is supported by intolerance documentation.
- Use statin plus ezetimibe for at least 12 continuous weeks; if statin intolerant, use ezetimibe alone for at least 12 continuous weeks.
- Document post-treatment LDL-C of at least 70 mg/dL or at least 55 mg/dL according to the patient’s high-risk or very-high-risk classification.
- For PCSK9 therapy, document at least 12 continuous weeks at the FDA-approved maximum HoFH dose and persistent LDL-C at or above the applicable threshold.
Statin Intolerance Documentation
When relying on statin intolerance, document the specific trials and adverse effects that satisfy the policy definition.
- The patient must be unable to tolerate at least two different statins, unless one statin caused rhabdomyolysis or clinically significant myonecrosis.
- Document confirmed intolerable statin-related myopathy or myalgia.
- Document resolution or significant improvement of symptoms or biomarker abnormalities after dose reduction or discontinuation.
- For rhabdomyolysis or myonecrosis, document muscle symptoms plus qualifying creatine kinase findings and acute renal failure or myoglobinuria when applicable.
Continuation Documentation
For continuation requests, provide the prior lomitapide approval, evidence of clinically significant LDL-C lowering, and documentation that the patient remains adherent to lomitapide.
- Continuation criteria must be met for re-authorization.
- Failure to document clinically significant LDL-C lowering or adherence may result in denial as not medically necessary.
Failure to Meet Coverage Criteria
Coverage can be denied when benefits are unavailable, medical-necessity requirements are not met, or patient-selection criteria are not satisfied.
- Lomitapide is eligible only when the member’s contract provides applicable benefits.
- Patient-selection criteria must be met unless the policy specifically identifies the failure as not medically necessary.
- Use that does not meet the applicable criteria may be treated as investigational.
Insufficient Prerequisite Therapy
Lomitapide is considered not medically necessary when the patient has not tried the required prerequisite medications for at least 12 weeks or the required treatment duration is not documented.
- Document at least 12 continuous weeks of the required statin and ezetimibe regimen, or ezetimibe without a statin when statin intolerant.
- Document at least 12 continuous weeks of maximum-dose PCSK9-inhibitor therapy when applicable.
- Missing treatment dates, doses, adherence evidence, or persistent LDL-C results creates denial risk.
Re-authorization Failure
Re-authorization may be denied as not medically necessary when the patient did not previously meet initial criteria, did not receive prior approval, has not achieved clinically significant LDL-C lowering, or is not adherent to lomitapide.
- Submit the prior approval and continuation clinical records with each re-authorization request.
Nonadherence
Lomitapide may be denied as not medically necessary when the patient is not adherent to the cholesterol-lowering regimen.
- Document adherence to prerequisite lipid-lowering medications and lomitapide when requesting continuation.
- Address gaps in therapy, missed doses, or other evidence of nonadherence before submitting the request.
Investigational Use Not Covered
Investigational or experimental medical treatments, drugs, devices, biological products, and treatment provided under the investigational arm of a clinical trial are not covered.
- Use of lomitapide when patient-selection criteria are not met may be considered investigational, except where the policy expressly classifies the failure as not medically necessary.
Avoid Prohibited Combination Therapy
Do not use Juxtapid in combination with Kynamro or PCSK9 inhibitors. Confirm the patient’s complete medication list before authorization and during treatment.
- Avoid combination with Kynamro (mipomersen).
- Avoid combination with PCSK9 inhibitors such as Repatha (evolocumab) or Praluent (alirocumab).
Combination With ACL Inhibitors
Do not use Juxtapid in combination with ATP-citrate lyase (ACL) inhibitors. Review all lipid-lowering therapy before approval and document that prohibited combination therapy is not being used.
- The policy prohibits combination use with the ACL-inhibitor class.
- Resolve or document discontinuation of an ACL inhibitor before initiating or continuing Juxtapid.
Therapeutic Background
Lomitapide is an oral microsomal triglyceride transfer protein inhibitor used as an adjunct to a low-fat diet, exercise, and other LDL-C therapies for adults and pediatric patients aged 2 years and older with homozygous familial hypercholesterolemia (HoFH). It reduces production of apolipoprotein B-containing lipoproteins and is intended to reduce LDL-C. Because lomitapide may cause hepatotoxicity and hepatic fat accumulation, liver-related laboratory testing is required before and during treatment, and the drug is available only through the Juxtapid REMS Program.
Policy Definitions
Initial Therapy
Continuation and Re-authorization
Re-authorization Criteria
Re-authorization requires ALL listed continuation criteria.
Lomitapide continuation
- The patient previously met the initial lomitapide criteria and received approval.
Prior approval must be documented.
- The patient has achieved clinically significant LDL-C lowering and remains adherent to lomitapide.Clinically significant LDL-C lowering
Updated Continuation Therapy Criteria
Continued therapy requires reauthorization under the updated policy criteria.
Continuation therapy
- The patient previously met the initial lomitapide criteria and received approval.
Reauthorization is required for continued therapy.
- The patient has achieved clinically significant LDL-C lowering.Clinically significant LDL-C lowering
- The patient remains adherent to lomitapide.
Failure to meet the continuation requirements may be considered not medically necessary.
Required Precursor Therapy
| Step | Prerequisite therapy | Requirement | Exception or result |
|---|---|---|---|
| 1 | High-intensity statin at the maximum daily dose, or a maximally tolerated stable daily statin dose when maximum-dose high-intensity therapy was not tolerated | At least 12 continuous weeks | Maximum-dose examples: atorvastatin ≥80 mg daily or rosuvastatin ≥40 mg daily |
| 2 | Generic ezetimibe 10 mg daily with the statin | At least 12 continuous weeks | For statin intolerance, use generic ezetimibe 10 mg daily without a statin for at least 12 continuous weeks |
| 3 | PCSK9 inhibitor at the FDA-approved maximum dose for HoFH | At least 12 continuous weeks | Examples: evolocumab 420 mg once every 2 weeks or alirocumab 150 mg once every 2 weeks; persistent LDL-C must remain ≥70 mg/dL for high-risk or ≥55 mg/dL for very-high-risk patients |
| 4 | Lomitapide | Consider after the required prerequisite therapy | PCSK9 inhibitor therapy is not required when the patient has two LDL-receptor-negative alleles or is 2 to 9 years of age |
| Therapy | Updated prerequisite requirement | Applicable exception |
|---|---|---|
| Maximally tolerated statin | Use before or with lomitapide as part of prerequisite lipid-lowering therapy | The updated criteria address use of maximally tolerated statin therapy; statin-intolerant patients are subject to the stated exception |
| Ezetimibe | Use before or with lomitapide as part of prerequisite lipid-lowering therapy | Subject to the updated patient-selection criteria |
| PCSK9 inhibitor | Use when appropriate before or with lomitapide | Not required for patients with two LDL-receptor-negative alleles or patients 2 to 9 years of age |
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.